I normally don't repost posts from other boards, but in

New Post Public Reply Private Reply Replies (4) Message Board
HHIGambler
5,157
I normally don't repost posts from other boards, but in this case, I'll make an exception. This was posted by a first-time poster.


elonmarx Tuesday, 07/07/20 12:46:07 AM
Re: None 0
Post # 91465 of 91499

I'm an MD and I generally stay away from Biotechs due to intense speculation and so many variables that exist between product inception and approval that are out of ones control.

With CYDY I think for the first time in my career I have truly seen the stars align.

Let me begin by saying I am NOT a savvy investor with formal investment training, access to the best financial firms or legions of analysts from B-school. Therefore, my decision to invest rests HEAVILY on the science itself. So far, it has served me well.

Leronlimab truly is a gem of a drug, which without exaggeration could end a pandemic, revive economies, and alter the course of modern medicine. However, I think most of us are unable to visualize the extent of its possible impact. Imagine asking Alexander Fleming how his mouldy petri dish would change the world. This drug very well may be to T cell mediated / autoimmune processes what penicillin is to bacterial diseases.

The usage of leronlimab to treat the auto inflammatory state triggered by covid was a stroke of genius. I think Dr. Seethamraju was brilliant in using this therapy, and I think Dr. Bruce Patterson's team was brilliant in recognizing the marked elevation of RANTES (the CCR5 ligand) in these patients.

What absolutely sold me on the mechanism of action was the fact that out of curiosity I decided to question the other findings of COVID-19. What about those kids with the Kawasaki-type syndromes? what about those mysterious petechial rashes?

I did my own research on PubMed and guess what? There is plenty of evidence from the early 2000s and before, that RANTES is significantly elevated in Kawasaki's disease. Guess what else i'ts elevated in? Henoch-Schonlein purpura.

The fact that the elevated RANTES was identified independently of this association with a kawasaki-type syndrome, really brings it home for me.

Lastly, if this is true, then Kawasaki syndrome and HSP are both likely triggered by a viral insult, which then results in upregulation in RANTES production and the recruitment of T cells to the area and resultant overproduction of inflammatory molecules.

Many autoimmune conditions are likely a combination of genetic predisposition coupled with a viral or environmental trigger. The reason why most people aren't grasping the magnitude of this discovery is because they don't realize the sheer number of auto-immune processes which up until now have had no clear trigger, and no real clear mechanism by which to treat safely and effectively.

I am absolutely a believer in the science, and only the science. Do your own research, but drugs like this don't come often. I hope its the real deal and some unforeseen political force doesn't keep it from realizing its full potential.

Really appreciate everyones thoughtful commentary on this board.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
My comments are just my opinions and should NOT be taken as investment advice.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hyperscale Recalibrates: AI Boom or Risky Bet?

Updated Category News Views 0

Is Hyperscale Making the Right Move? Hyperscale Data, Inc. waved goodbye to the Bitcoin mining days to clear the stage for artificial intelligence (AI). But is this strategic leap off the blockchain and into AI territory as golden as promised? Whisper around the street is it could turn into a $3 billion windfall. But let's chew through the details before toasting...

Continue Reading
ADA Audit Reveals Gaps in Event Management at 2026 Session

Updated Category News Views 2

Hold onto your hats, folks, because the American Diabetes Association (ADA) just dropped a bombshell report with findings that'll make your head spin if you're keyed into the healthcare sector. They’ve wrapped this up in a bow of accountability, but let's dig into the crux of it. Behind the Controversy: The New Orleans Incident This all harks back to an incident on June...

Continue Reading
Corner Bakery Cafe Unveils Fall Treat Lineup

Updated Category News Views 3

Get Ready for a Fall Feast at Corner Bakery Cafe Pumpkin spice season is here, whether you're thrilled or grumbling about it. Corner Bakery Cafe is throwing its hat in the seasonal ring, bringing back its crowd-pleaser Pumpkin Latte—available hot, iced, or as a cold brew. They're also rolling out a lineup full of tempting treats aimed to capture those autumn cravings....

Continue Reading
3D Cloud Expands with Enhanced Visual CPQ Capabilities

Updated Category News Views 2

Changing the Game in Complex Product Configuration It's a new dawn in how customers tinker with custom products. Talk about blasting through the old convolutions of configuration. 3D Cloud's fresh offering makes product configuration a breeze, very much like choosing ingredients for a custom sandwich and seeing it come to life. Frankly, the introduction of 3D Visual CPQ...

Continue Reading
BKF Welcomes Andrew Esposito as New CFO

Updated Category News Views 5

BKF's Strategic Move: Andrew Esposito Steps In Don't walk past a headline like this without feeling the pulse of BKF's ambitious strides in the AEC industry. BKF, a heavyweight in the architecture, engineering, and construction sector, has tapped Andrew Esposito as its new Chief Financial Officer. Based out in sunny Oakland, California, they're looking to crank up their...

Continue Reading
American Tungsten's Bold Play in Nevada is Noteworthy

Updated Category News Views 10

American Tungsten's Shifting Focus Today we're chewing over some intriguing moves from American Tungsten & Antimony, Ltd. (ASX: AT4; OTCQX: ATALF). These cats are eyeing a chunk of the strategic metals market. They've engaged Metso Finland Oy to whip up a Scoping Study for an ammonium paratungstate (APT) production circuit at their Del Sol Refinery in Nevada. Why Tungsten...

Continue Reading
Trua Embarks on New Senior Support Journey in GA

Updated Category News Views 2

A New Chapter for Senior Care in South Fulton Here's a story that's probably tugging a few heartstrings: Trua Senior Living Locators has kicked off operations in South Fulton. This isn't just another business launch; it's a tale deeply rooted in personal experience. The man at the helm, Fred Giahi, knows firsthand the trials and tribulations families face when dealing...

Continue Reading
Charter CFO to Speak at Citi TMT Conference 2026

Updated Category News Views 9

Charting Charter's Future Moves at the Citi TMT Conference There's something electric about a company like Charter Communications showing up at a big-deal event like the Citi Global TMT Conference. It's not just another day in the office when Jessica Fischer, the Chief Financial Officer, steps up to the mic on September 10, 2026. Investors better have their ears perked...

Continue Reading
BD&J Shines in Elite 2026 Legal Ranking for California

Updated Category News Views 2

A Rare Nod from Chambers and Partners Now and then, the legal spotlight lands in places you don't quite expect. This time, it’s BD&J—a stalwart of the personal injury field—grabbing the limelight right from under the noses of California's Big Law giants. This firm has been pegged as a top contender in the 2026 Chambers and Partners Spotlight Guide. And let me tell...

Continue Reading
Nozomi Networks: Leading OT Security in 2026

Updated Category News Views 6

One Year of Massive Wins for Nozomi Networks Here's a wild trajectory: Nozomi Networks has been firing on all cylinders in 2026, capturing attention not just from analysts but also from anyone with a stake in the security game. The company’s impressive run was highlighted most recently when they were crowned a Leader in The Forrester Wave: Operational Technology...

Continue Reading

Top 5 Most Recently Viewed Articles

Valneva Updates IXCHIQ® Vaccine Guidelines for Seniors Age 65+

Updated Category News Views 152

Valneva Updates IXCHIQ® Vaccine Guidelines for Seniors Age 65+ Valneva SE (NASDAQ: VALN; Euronext Paris: VLA), a renowned specialty vaccine company, has made significant strides in its ongoing commitment to public health. As of now, the European Medicines Agency (EMA) has initiated a review of the chikungunya vaccine, IXCHIQ®, after receiving reports concerning adverse...

Continue Reading
Discover the Inspiring Journey of ''Sunshine in My Heart''

Updated Category News Views 109

Introducing ''Sunshine in My Heart'' Xulon Press proudly presents the first volume of My Sun & Shade book series, an empowering narrative aimed at women, chronicling profound moments of personal growth and spiritual enlightenment. A Journey of Faith and Resilience Written by Angela M. Viola, this memoir invites readers into a deeply personal story that unfolds the themes...

Continue Reading
Soma Gold Expands Operations with Escondida Mine Acquisition

Updated Category News Views 294

Soma Gold Announces New Mine Acquisition Soma Gold Corp. (TSXV: SOMA) has just made headlines with its latest decision to acquire the Escondida Mine, a significant move that could greatly impact its growth and production capabilities in the gold mining sector. Key Acquisition Details The Escondida Mine stretches over 1,051 hectares, fully permitted and poised for rapid...

Continue Reading
Artera Showcases Innovative Solutions for Healthcare Engagement

Updated Category News Views 176

Artera Unveils New Product Offerings at Heartbeat Conference In a groundbreaking event, Artera, a leading SaaS digital health innovator, recently showcased its latest product offerings aimed at revolutionizing patient interactions. This significant reveal took place during the vibrant Artera Heartbeat Customer Conference, which brought together over 300 health system...

Continue Reading
Investors of Tandem Diabetes Care Should Review Potential Claims

Updated Category News Views 218

Understanding the Situation with Tandem Diabetes Care, Inc. Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is currently under scrutiny concerning potential securities claims. Investors have reason to be vigilant as their rights might be affected by recent developments within the company. What is Being Investigated? The Rosen Law Firm, a reputable global investor rights law...

Continue Reading